Open AccessA beneficial cardiometabolic health profile associated with dietary supplement use: A cross-sectional study
Author(s) -
Paul F. Jacques,
Gail Rogers
Publication year - 2023
Publication title -
international journal for vitamin and nutrition research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.336
H-Index - 57
eISSN - 1664-2821
pISSN - 0300-9831
DOI - 10.1024/0300-9831/a000701
Subject(s) - medicine , multivitamin , confidence interval , diabetes mellitus , cross sectional study , national health and nutrition examination survey , cholesterol , ldl cholesterol , insulin , endocrinology , population , vitamin , environmental health , pathology
. As a follow-up to an earlier study demonstrating healthier cardiometabolic profiles among long-term multiple dietary supplement (LTMDS) users, we examined if cardiometabolic health benefits associated with LTMDS use persisted with aging. The study is based on LTMDS users from North America and 2007–2010 NHANES participants who were used for comparison to the LTMDS users. NHANES subjects were classified as non-dietary supplement (NS) users, single supplement/single purpose supplement (SS) users, multivitamin/mineral supplement (MVMS) users, and multiple dietary supplement (MDS) users. Supplement groups were compared for total, HDL and LDL cholesterol; triglycerides; glucose; insulin; CRP and HbA1c ≥ 6.5%, adjusting for age, sex, income, education, BMI, history of CVD, and medications for hypercholesterolemia and diabetes. Geometric mean (95% confidence interval) LDL cholesterol was significantly lower (P < 0.05) for all supplement groups (SS: 110 (104–117) mg/dL; MVMS: 113 (107–119) mg/dL; MDS: 115 (111–118) mg/dL; LTMDS: 112 (105, 119) mg/dL) compared with the NS users (122 (118–126) mg/dL). Compared with the NS group, MDS users had significantly (P < 0.05) lower mean total cholesterol (198 (194–201) vs 201 (197, 206) mg/dL), MDS and LTMDS users higher mean HDL cholesterol (54.2 (53.3–55.1) and 60.0 (57.4, 62.7) mg/dL vs 52.0 (50.8–53.3) mg/dL), LTMDS users lower fasting glucose (100 (98–103) vs 105 (103–106) mg/dL), SS and MDS users lower insulin (8.4 (7.4–9.6) and 9.1 (8.3–9.9) vs 10.2 (9.4–11.1) μIU/mL), and MDS users lower CRP (% ≥ 1.5 mg/L, 50.8 (47.9–53.6) vs 57.0 (52.4–61.6) %). These findings add to the evidence that use of dietary supplements may provide cardiometabolic health benefits.